

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**THIRTY SIXTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM SEPTEMBER 1, 2022 THROUGH SEPTEMBER 30, 2022**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	September 1, 2022 through September 30, 2022
Monthly Fees Incurred:	\$53,219.00

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$8.00

Total Fees and Expenses Due: \$53,227.00

This is a: X monthly _____interim _____final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.00	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00
Docket No. 2848 Filed on 5/12/2021	2/1/2021 – 2/28/2021	\$381,199.00	\$9.99	\$377,458.99	\$9.99
Docket No. 2849 Filed on 5/12/2021	3/1/2021 – 3/31/2021	\$513,645.00	\$0.00	\$509,895.00	\$0.00
Docket No. 3017 Filed on 6/11/2021	4/1/2021 – 4/30/2021	\$415,904.00	\$0.00	\$412,154.00	\$0.00
Docket No. 3225 Filed on 7/15/2021	5/1/2021 – 5/31/2021	\$363,711.00	\$40.00	\$360,001.00	\$40.00
Docket No. 3747 Filed on 9/9/2021	6/1/2021 – 6/30/2021	\$303,427.50	\$0.00	\$299,677.50	\$0.00

PRIOR APPLICATIONS (cont.):

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 3798 Filed on 9/21/2021	7/1/2021 – 7/31/2021	\$431,630.50	\$135.81	\$427,880.50	\$135.81
Docket No. 3941 Filed on 10/14/2021	8/1/2021 – 8/31/2021	\$284,159.00	\$20.94	\$280,409.00	\$20.94
Docket No. 4097 Filed on 11/11/2021	9/1/2021 – 9/30/2021	\$244,958.50	\$0.00	\$241,208.50	\$0.00
Docket No. 4225 Filed on 12/15/2021	10/1/2021 – 10/31/2021	\$368,998.50	\$40.00	\$367,498.50	\$40.00
Docket No. 4311 Filed on 1/26/2022	11/1/2021 – 11/30/2021	\$255,094.50	\$1,160.04	\$253,594.50	\$1,160.04
Docket No. 4312 Filed on 1/26/2022	12/1/2021 – 12/31/2021	\$192,786.50	\$0.00	\$191,286.50	\$0.00
Docket No. 4395 Filed on 2/25/2022	1/1/2022 – 1/31/2022	\$314,564.00	\$0.00	\$313,064.00	\$0.00
Docket No. 4654 Filed on 4/12/2022	2/1/2022 – 2/28/2022	\$181,198.50	\$8.00	\$178,888.84	\$8.00
Docket No. 4826 Filed on 5/16/2022	3/1/2022 – 3/31/2022	\$267,504.00	\$44.03	\$265,194.33	\$44.03
Docket No. 4833 Filed on 5/16/2022	4/1/2022 – 4/30/2022	\$175,704.00	\$0.00	\$173,394.33	\$0.00
Docket No. 4950 Filed on 7/12/2022	5/1/2022 – 5/31/2022	\$98,099.50	\$0.00	\$78,479.60	\$0.00
Docket No. 5005 Filed on 8/8/2022	6/1/2022 – 6/30/2022	\$53,624.00	\$0.00	\$42,899.20	\$0.00
Docket No. 5051 Filed on 8/31/2022	7/1/2022 – 7/31/2022	\$53,023.00	\$0.00	\$42,418.40	\$0.00
Docket No. 5132 Filed on 10/12/2022	8/1/2022 – 8/31/2022	\$35,470.00	\$0.00	\$28,376.00	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, \$15,000, \$15,000, \$15,000, \$6,000, and \$6,929 were allocated evenly across fees from the first, second, third, fourth, fifth, sixth, seventh, and eighth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from September 1, 2022 through and including September 30, 2022 (the “**Fee Period**”) amount to:

Professional Fees	\$53,219.00
Expenses	<u>8.00</u>
TOTAL	<u>\$53,227.00</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$42,575.20
Expenses at 100%	<u>8.00</u>
TOTAL	<u>\$42,583.20</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A”**.
4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B”**.

5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C”**.
6. A summary of expenses incurred during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “D”**.
7. Detailed breakdown of the expenses incurred during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “E”**.
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than November 29, 2022 (the **“Objection Deadline”**), setting forth the nature of the objection and the amount of fees or expenses at issue (an **“Objection”**).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
November 15, 2022

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
1166 Avenue of the Americas, 15th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY PROFESSIONAL****FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022**

Professional	Position	Specialty	Billing Rate	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,200	15.6	\$ 18,720.00
Bromberg, Brian	Sr Director	Restructuring	890	30.4	27,056.00
Suric, Emil	Sr Director	Restructuring	890	2.0	1,780.00
Kurtz, Emma	Sr Consultant	Restructuring	655	7.1	4,650.50
GRAND TOTAL				56.6	\$ 53,219.00

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	8.4	\$ 7,518.50
2	Cash & Liquidity Analysis	1.3	1,560.00
6	Asset Sales	3.8	3,630.00
7	Analysis of Domestic Business Plan	34.6	32,335.00
16	Analysis, Negotiate and Form of POR & DS	1.8	1,592.50
18	Review of Historical Transactions	3.8	3,816.00
28	Review of IAC Business Plan	2.9	2,767.00
GRAND TOTAL		56.6	\$ 53,219.00

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022

Task Category	Date	Professional	Hours	Activity
1	9/1/2022	Diaz, Matthew	1.1	Review Debtors' updated reporting analysis re: sales and cash.
1	9/1/2022	Diaz, Matthew	0.5	Review Debtors' Avrio analysis.
1	9/1/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/7/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/8/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/12/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/13/2022	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/14/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/15/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/19/2022	Diaz, Matthew	0.3	Review updated injunction order.
1	9/19/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/20/2022	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/21/2022	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/22/2022	Diaz, Matthew	0.7	Review latest monthly operating report to evaluate performance.
1	9/22/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/23/2022	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/27/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/28/2022	Diaz, Matthew	1.1	Review Debtors' latest reporting re: sales and cash.
1	9/29/2022	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/30/2022	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			8.4	
2	9/9/2022	Diaz, Matthew	0.6	Review Debtors' latest cash flow reporting.
2	9/13/2022	Diaz, Matthew	0.7	Review Debtors' updated cash flow analysis.
2 Total			1.3	
6	9/22/2022	Bromberg, Brian	1.4	Review de minimis asset procedures.
6	9/23/2022	Bromberg, Brian	0.6	Prepare comments on de minimis asset sale procedures.
6	9/23/2022	Diaz, Matthew	0.8	Review proposed de minimis asset sale procedures.
6	9/30/2022	Bromberg, Brian	1.0	Review and send comments on asset sale procedures to Debtors.
6 Total			3.8	
7	9/7/2022	Bromberg, Brian	1.3	Review and investigate ANDA issues.
7	9/7/2022	Suric, Emil	0.8	Research Accord ANDA filing and potential for earlier than anticipated LOE.
7	9/9/2022	Diaz, Matthew	1.1	Review Debtors' updated business plan.
7	9/12/2022	Bromberg, Brian	0.9	Continue to evaluate potential ANDA issues.
7	9/13/2022	Bromberg, Brian	1.1	Review Debtors' latest business plan.
7	9/13/2022	Bromberg, Brian	0.7	Evaluate potential impact of ANDA issues on latest business plan.
7	9/13/2022	Bromberg, Brian	0.3	Review materials to prepare for call with Debtors' advisors re: ANDA issues.
7	9/13/2022	Bromberg, Brian	1.6	Review generics business plan to evaluate impact of ANDA issues.
7	9/13/2022	Bromberg, Brian	0.7	Discuss ANDA issues with Debtors and their advisors.
7	9/13/2022	Kurtz, Emma	0.7	Attend call with the Company and their advisors re: Accord update.
7	9/13/2022	Suric, Emil	0.7	Attend call with Debtors and advisors to discuss Accord patent challenge.
7	9/14/2022	Bromberg, Brian	0.5	Attend call with internal team re: ANDA issues.
7	9/14/2022	Bromberg, Brian	0.6	Prepare summary of ANDA issues.
7	9/14/2022	Bromberg, Brian	0.4	Finalize and send update on ANDA issues.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022

Task Category	Date	Professional	Hours	Activity
7	9/14/2022	Bromberg, Brian	0.5	Discuss ANDA issues with counsel.
7	9/14/2022	Diaz, Matthew	0.8	Review Oxycontin patent status.
7	9/14/2022	Diaz, Matthew	0.7	Review Debtors' updated business plan.
7	9/14/2022	Kurtz, Emma	0.5	Attend call with internal team to discuss business plan and patent litigation update.
7	9/14/2022	Suric, Emil	0.5	Attend call with counsel to discuss Accord patent challenge.
7	9/15/2022	Bromberg, Brian	1.4	Review business plan projections and potential impact of ANDA.
7	9/15/2022	Bromberg, Brian	0.5	Attend call with HL and BR to discuss ANDA issues.
7	9/15/2022	Bromberg, Brian	0.6	Review prior OxyContin forecasts.
7	9/15/2022	Bromberg, Brian	0.5	Prepare updated summary re: ANDA issues for working group.
7	9/15/2022	Diaz, Matthew	0.5	Participate in call with BR and Houlihan to discuss the Oxycontin patents.
7	9/15/2022	Diaz, Matthew	0.4	Draft correspondence to counsel re: Oxycontin patents.
7	9/15/2022	Kurtz, Emma	0.5	Attend call with Houlihan and Brown Rudnick to discuss patents.
7	9/16/2022	Diaz, Matthew	0.9	Prepare updates to summary for the Committee re: ANDA issues.
7	9/20/2022	Bromberg, Brian	0.4	Review FDA inspection and 483 response letter.
7	9/20/2022	Bromberg, Brian	0.8	Review ANDA summary for Committee to prepare updates.
7	9/20/2022	Bromberg, Brian	0.3	Finalize and send draft ANDA summary to the working group in advance of call.
7	9/20/2022	Bromberg, Brian	0.4	Review potential FDA inspection issues.
7	9/20/2022	Bromberg, Brian	0.6	Review latest business plan.
7	9/20/2022	Bromberg, Brian	0.6	Review business plan cash flow forecast.
7	9/20/2022	Bromberg, Brian	0.6	Discuss ANDA issues with working group.
7	9/20/2022	Diaz, Matthew	0.8	Review Purdue patent considerations.
7	9/21/2022	Bromberg, Brian	0.9	Finalize and send ANDA summary to AHC.
7	9/21/2022	Diaz, Matthew	0.6	Draft correspondence to Committee on certain issues in lieu of meeting.
7	9/22/2022	Bromberg, Brian	0.2	Coordinate call for FDA inspection issues.
7	9/23/2022	Bromberg, Brian	1.0	Attend call with team re: FDA inspection.
7	9/23/2022	Bromberg, Brian	0.9	Prepare summary of FDA inspection issues.
7	9/23/2022	Shafer, Patterson	1.0	Attend call with team to discuss FDA inspection and 483 response letter.
7	9/23/2022	Shafer, Patterson	0.5	Prepare analysis of 483 response letter and share with team.
7	9/26/2022	Bromberg, Brian	0.7	Draft AHC update on FDA issues.
7	9/26/2022	Bromberg, Brian	1.0	Edit FDA update based on comments from team.
7	9/26/2022	Bromberg, Brian	0.7	Provide further comments to Debtors on asset sale procedures.
7	9/27/2022	Bromberg, Brian	0.5	Finalize and send update on FDA inspection.
7	9/30/2022	Bromberg, Brian	0.4	Review Wilson business plan data.
7	9/30/2022	Bromberg, Brian	0.5	Review business plan backup information.
7	9/30/2022	Diaz, Matthew	1.5	Review updated business plan materials to evaluate changes.
7 Total			34.6	
16	9/13/2022	Diaz, Matthew	0.5	Participate in bi-weekly call with the Debtors' advisors to discuss current Company developments.
16	9/13/2022	Kurtz, Emma	0.3	Attend bi-weekly professionals call to discuss case status and emergence prep.
16	9/27/2022	Bromberg, Brian	0.6	Participate in call with Debtors' advisors re: case updates, including the business plan.
16	9/27/2022	Kurtz, Emma	0.4	Attend biweekly professionals call to discuss case updates and emergence preparation.
16 Total			1.8	
18	9/2/2022	Diaz, Matthew	0.8	Review of Purdue case summaries.
18	9/26/2022	Bromberg, Brian	0.4	Review Sackler responses on net asset reports.
18	9/27/2022	Bromberg, Brian	1.1	Review Sackler net asset reports to evaluate information request.
18	9/27/2022	Bromberg, Brian	0.6	Draft suggested response re: updated net asset reports.
18	9/27/2022	Diaz, Matthew	0.6	Review of the Sackler information request and related reporting.
18	9/29/2022	Bromberg, Brian	0.3	Prepare updates to suggested response for net asset reports.
18 Total			3.8	
28	9/6/2022	Bromberg, Brian	0.9	Review previously provided IAC information.
28	9/6/2022	Bromberg, Brian	1.0	Participate in call with IAC management re: financial updates.
28	9/6/2022	Bromberg, Brian	0.4	Summarize IAC call for team and Houlihan.
28	9/12/2022	Diaz, Matthew	0.6	Review IAC operating results.
28 Total			2.9	
Grand Total			56.6	

EXHIBIT D**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF EXPENSES****FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022**

Expense Type	Amount
Other	\$ 8.00
Grand Total	\$ 8.00

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD SEPTEMBER 1, 2022 TO SEPTEMBER 30, 2022

Date	Professional	Expense Type	Expense Detail	Amount
9/20/2022	Bromberg, Brian	Other	Flight internet charge to complete case work.	8.00
Other Total				\$ 8.00
Grand Total				\$ 8.00